Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 177

Sort by

Sort Order Select

Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Blood (2019) 134 (Supplement_1): 49.

https://doi.org/10.1182/blood-2019-122374

Published: 2019

Journal Articles

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma

Alessandro Lagana, PhD, Sherry Bhalla, Adolfo Aleman, Anna Huo-Chang Mei, MS, Violetta Leshchenko, PhD, Yosef Landesman, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Deepu Madduri, MD, Joshua R Richter, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 3101.

https://doi.org/10.1182/blood-2019-130753

Published: 2019

Journal Articles

Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma

Taiga Nishihori, MD, Jonathan L. Kaufman, MD, James E. Hoffman, Kristin Blouch, Sunil Pandit, Emily Butler, Amit Jain, Yuehui Wu, M. Phillip DeYoung, Aisha N. Hasan, Aaron P. Rapoport

Blood (2019) 134 (Supplement_1): 3134.

https://doi.org/10.1182/blood-2019-128059

Published: 2019

Journal Articles

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Blood (2019) 134 (Supplement_1): 1269.

https://doi.org/10.1182/blood-2019-130996

Published: 2019

Journal Articles

Transcriptome Alterations of Isolated Primary Bone Marrow Endothelial Cells Provide Insigt to MGUS and Multiple Myeloma Pathobiology

Sandro Bräunig, MSc, Dimitra Zacharaki, PhD, Hongzhe Li, PhD, Hooi Ching Lim, PhD, Stefan Lang, PhD, Thoas Fioretos, MD PhD Prof., Stefan Scheding, MD

Blood (2019) 134 (Supplement_1): 4373.

https://doi.org/10.1182/blood-2019-128024

Published: 2019

Journal Articles

Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER ® ) Molecules

Sebastian Bunk, PhD, Martin Hofmann, PhD, Felix Unverdorben, PhD, Meike Hutt, PhD, Gabriele Pszolla, PhD, Frank Schwöbel, PhD, Claudia Wagner, PhD, Sara Yousef, PhD, Heiko Schuster, PhD, Sarah Missel, PhD, Oliver Schoor, PhD, Toni Weinschenk, PhD, Harpreet Singh-Jasuja, PhD, Dominik Maurer, PhD, Carsten Reinhardt, MD

Blood (2019) 134 (Supplement_1): 3368.

https://doi.org/10.1182/blood-2019-129958

Published: 2019

Journal Articles

Epigenetic Drug Treatment Induces Presentation of New Class of Non-Exonic, Cryptic Neoantigens in Acute Myeloid Leukemia Cells

Martin G. Klatt, MD, Sung S. Mun, Nicholas D. Socci, PhD, Tatyana Korontsvit, MD, Tao Dao, MD PhD, David A. Scheinberg, MD PhD

Blood (2018) 132 (Supplement 1): 2717.

https://doi.org/10.1182/blood-2018-99-113691

Published: 2018

Journal Articles

Mass Spectrometry-Based Immunopeptidome Analysis of Acute Myeloid Leukemia Cells Under Decitabine Treatment Delineates Induced Presentation of Cancer/Testis Antigens on HLA Class I Molecules

Jens Bauer, Nora Zieger, Annika Nelde, Leon Bichmann, Helmut R. Salih, MD, Lothar Kanz, Hans-Georg Rammensee, Stefan Stevanovic, Juliane S. Walz

Blood (2018) 132 (Supplement 1): 5223.

https://doi.org/10.1182/blood-2018-99-113357

Published: 2018

Journal Articles

Somatic PRAME Deletions Are Associated with Decreased Immunogenicity, Apoptosis Resistance and Poor Outcomes in Diffuse Large B-Cell Lymphoma

Katsuyoshi Takata, MD PhD, Daisuke Ennishi, MDPhD, Ali Bashashati, Saeed Saberi, Elena Viganò, PhD, Shannon Healy, PhD, Julie S Nielsen, Gianluca D' Antonio, Brad H Nelson, Sohrab P Shah, Joseph M Connors, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Christian Steidl, MD

Blood (2018) 132 (Supplement 1): 667.

https://doi.org/10.1182/blood-2018-99-113516

Published: 2018

Journal Articles

TFDP3 and DDX53 are Highly Re-Expressed after One Cycle of Azacitidine in Myelodysplastic Syndrome Patients Achieving Complete Response: A Cancer Testis Antigen RNA-Seq Screening

Ana M Hurtado López, Tzu Hua Chen-Liang, Joaquín Panadero, Eduardo José Salido, MD, Victor Beltrán, Begoña Muiña, Noelia Navarro-Villamor, Inés Calabria, Ana Isabel Antón, Francisco José Ortuño, Vicente Vicente, MD PhD, Andres Jerez

Blood (2018) 132 (Supplement 1): 4340.

https://doi.org/10.1182/blood-2018-99-117851

Published: 2018

Journal Articles

Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL)

Lorenzo Falchi, MD, Jennifer Kimberly Lue, MD, Francesca Montanari, MD, Enrica Marchi, MD, PhD, Jennifer E Amengual, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Karen Khan, BSN, Hyea Kim, NP-BC, Laine E. Atkins, RN, Aishling M. Rada, RN, Cremers Serge, PhD PharmD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 1002.

https://doi.org/10.1182/blood-2018-99-116605

Published: 2018

Journal Articles

Efficacy, Toxicity and Targets for Adoptive Cellular Therapy in Multiple Myeloma: A Systematic Review

Muhammad Usman, MD, Muhammad Junaid Tariq, MD, Awais Ijaz, MD, Muhammad Asad Fraz, MD, Ali Younas Khan, MD, Nadia Carenina Nunes Cavalcante Parr, MD, Muhammad Jahanzeb Khalil, MD, Arveen Asghar, Seren Durer, MD, Ceren Durer, MD, Malik Qistas Ahmad, MD MBBS, Chaudhry Saad Sohail, MD, Mustafa Nadeem Malik, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5649.

https://doi.org/10.1182/blood-2018-99-109944

Published: 2018

Journal Articles

Azacitidine and Romidepsin Synergize to Induce Expression of Cancer Testes Antigens (CTA) and Shift Peripheral T-Cell Lymphoma (PTCL) Cell Lines Toward a Th1-like Phenotype

Cristina Kinahan, BS, Luigi Scotto, PhD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 2845.

https://doi.org/10.1182/blood-2018-99-117344

Published: 2018

Journal Articles

Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements

Blood (2018) 132 (13): 1386–1398.

https://doi.org/10.1182/blood-2018-03-838524

Published: 2018

Includes: Supplemental data

Journal Articles

Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02 + Patients with Advanced Multiple Myeloma: Long Term Follow-up (NCT01352286)

Aaron P. Rapoport, MD, Edward A Stadtmauer, MD, Karen Chagin, MD, Thomas Faitg, Malini Iyengar, Trupti Trivedi, Elliot Norry, MD, Tom Holdich, MD, Gwendolyn Binder-Scholl, PhD, Rafael Amado, MD, Frank Fang

Blood (2017) 130 (Supplement 1): 845.

https://doi.org/10.1182/blood.V130.Suppl_1.845.845

Published: 2017

Journal Articles

Azacytidine and Decitabine Exhibit Differential Effects on Cytotoxicity and Methylation and Exhibit Class Synergy with Hdaci in Models of Ptcl

Luigi Scotto, PhD, Cristina Kinahan, B.S., Beatrice Casadei, MD, Owen A. O'Connor, MD, PhD

Blood (2017) 130 (Supplement 1): 2743.

https://doi.org/10.1182/blood.V130.Suppl_1.2743.2743

Published: 2017

Journal Articles

Global and Targeted RNA-Sequencing Assessment of Cancer Testis Antigen Re-Expression Following Azacitidine in Myelodysplastic Syndromes

Ana M Hurtado, Tzu Hua Chen-Liang, Joaquín Panadero, Eduardo José Salido, MD, Victor Beltrán, Begoña Muiña, Noelia Navarro-Villamor, Inés Calabria, Ana Isabel Antón, Andres Jerez

Blood (2017) 130 (Supplement 1): 1695.

https://doi.org/10.1182/blood.V130.Suppl_1.1695.1695

Published: 2017

Journal Articles

Altered Transcriptome Uniquely Associated with AML Vs. Normal Hematopoiesis

Yu Fan, Ying Hu, Cu Nguyen, Chunhua Yan, Rhonda E. Ries, MA, Hamid Bolouri, PhD, Jenny L. Smith, MSc, MD, Qingrong Chen, E. Anders Kolb, MD, Soheil Meshinchi, MD PhD, Daoud Meerzaman

Blood (2017) 130 (Supplement 1): 3792.

https://doi.org/10.1182/blood.V130.Suppl_1.3792.3792

Published: 2017

Journal Articles

Immune Gene Expression Profiling in Children and Adults with Acute Myeloid Leukemia Identifies Distinct Phenotypic Patterns

Jayakumar Vadakekolathu, PhD, Tasleema Patel, BSc, Stephen Reeder, BSc, Heidi Schaarschmidt, BSc, Marc Schmitz, MD, Martin Bornhäuser, MD, Sarah E. Warren, PhD, Tressa Hood, MS, Patrick Danaher, PhD, Alessandra Cesano, Joseph M. Beechem, PhD, A. Graham Pockley, PhD, Sarah K Tasian, MD, Sergio Rutella, MDPhDFRCPath

Blood (2017) 130 (Supplement 1): 3942.

https://doi.org/10.1182/blood.V130.Suppl_1.3942.3942

Published: 2017

Journal Articles

Development of T-Cell Therapy By Exploiting Modified Antibodies Specific for A2/NY-ESO-1 for Refractory Myeloma

Masaki Maruta, MD, Toshiki Ochi, MD PhD, Kazushi Tanimoto, MD PhD, Taichi Azuma, MD PhD, Hiroshi Fujiwara, MD PhD, Masaki Yasukawa, MD PhD

Blood (2017) 130 (Supplement 1): 1913.

https://doi.org/10.1182/blood.V130.Suppl_1.1913.1913

Published: 2017

NARROW

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma

Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Transcriptome Alterations of Isolated Primary Bone Marrow Endothelial Cells Provide Insigt to MGUS and Multiple Myeloma Pathobiology

Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER ® ) Molecules

Epigenetic Drug Treatment Induces Presentation of New Class of Non-Exonic, Cryptic Neoantigens in Acute Myeloid Leukemia Cells

Mass Spectrometry-Based Immunopeptidome Analysis of Acute Myeloid Leukemia Cells Under Decitabine Treatment Delineates Induced Presentation of Cancer/Testis Antigens on HLA Class I Molecules

Somatic PRAME Deletions Are Associated with Decreased Immunogenicity, Apoptosis Resistance and Poor Outcomes in Diffuse Large B-Cell Lymphoma

TFDP3 and DDX53 are Highly Re-Expressed after One Cycle of Azacitidine in Myelodysplastic Syndrome Patients Achieving Complete Response: A Cancer Testis Antigen RNA-Seq Screening

Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL)

Efficacy, Toxicity and Targets for Adoptive Cellular Therapy in Multiple Myeloma: A Systematic Review

Azacitidine and Romidepsin Synergize to Induce Expression of Cancer Testes Antigens (CTA) and Shift Peripheral T-Cell Lymphoma (PTCL) Cell Lines Toward a Th1-like Phenotype

Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements

Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02 + Patients with Advanced Multiple Myeloma: Long Term Follow-up (NCT01352286)

Azacytidine and Decitabine Exhibit Differential Effects on Cytotoxicity and Methylation and Exhibit Class Synergy with Hdaci in Models of Ptcl

Global and Targeted RNA-Sequencing Assessment of Cancer Testis Antigen Re-Expression Following Azacitidine in Myelodysplastic Syndromes

Altered Transcriptome Uniquely Associated with AML Vs. Normal Hematopoiesis

Immune Gene Expression Profiling in Children and Adults with Acute Myeloid Leukemia Identifies Distinct Phenotypic Patterns

Development of T-Cell Therapy By Exploiting Modified Antibodies Specific for A2/NY-ESO-1 for Refractory Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only